Примери за използване на Dose interruption на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Recommendations for dose interruptions in sJIA patients.
Recommendations for dose interruptions in sJIA and pJIA patients.
Management of overdose(including the use of calcium folinate and dose interruption).
Consider dose interruption or discontinuation of pomalidomide treatment.
The median time to first dose reduction was 43 days,and to first dose interruption was 33 days.
Dose interruption may become necessary in patients who experience worsening of liver function(see section 4.2).
If adverse reactions persist beyond a 28-day dose interruption, it is recommended that Zejula be discontinued.
After dose interruption a haemoglobin decrease of approximately 0.35 g/ dl(0.22 mmol/ l) per week is expected.
Most adverse reactions are reversible andcan be managed by symptomatic therapy, dose interruptions and dose reductions.
Nausea events led to dose interruption and dose reductions in 14% and 4%, respectively, of olaparib-treated patients.
All ISRs reported were non-serious Grade 1 events, andnone of the ISRs required patient withdrawal from treatment or dose interruption.
Anaemia was managed with dose interruptions and dose reductions(see section 4.2), and where appropriate with blood transfusions.
Of the 11 patients who experienced differentiation syndrome, 9(82%)recovered after treatment or after dose interruption of Xospata.
Dose interruptions occurred most frequently in the first 3 months and dose reductions in the first 3-6 months of treatment.
Management of signs orsymptoms of hepatic toxicity may require a dose interruption, or discontinuation of MYLOTARG(see section 4.2).
When dose interruption is required, consider resuming Odomzo at the same dose after resolution of the adverse reaction to≤ grade 1.
Among dasatinib-treated patients with drug-related pleural effusion(n=73), 45(62%)had dose interruptions and 30(41%) had dose reductions.
Male patients must use condoms during treatment and for 1 week after dose interruption and/or cessation of treatment if their partner is pregnant or is of childbearing potential not using effective contraception.
The majority of ISRs reported were Grade 1 events and all ISRs reported were non-serious andnone required patient withdrawal from treatment or dose interruption.
Management of some adverse reactions may require dose interruption and/or dose reduction as shown in Table 1, Table 2, Table 3, and Table 4.
Amongst 1,166 patients treated with lenvatinib, there were 4 cases(0.3%) of PRES(0.3% were Grade 3 or 4),all of which resolved after treatment and/or dose interruption, or permanent discontinuation.
As thalidomide is found in semen, male patients must use condoms during treatment andfor 1 week after dose interruption and/ or cessation of treatment if their partner is pregnant or is of childbearing potential not using effective contraception.
Thrombocytopenia, or decreased platelet counts, was commonly reported with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation,dose reduction, and dose interruption(see section 4.8).
If the blood parameters remain clinically abnormal after 4 weeks of Lynparza dose interruption, bone marrow analysis and/or blood cytogenetic analysis are recommended.
After 8 weeks on tofacitinib 10 mg twice daily in OCTAVE Open, remission was achieved in 35%(20/58) patients who received tofacitinib 5 mg twice daily in OCTAVE Sustain and 40%(40/99)patients with dose interruption in OCTAVE Sustain.
As a precaution,all male patients taking pomalidomide should use condoms throughout treatment duration, during dose interruption and for 7 days after cessation of treatment if their partner is pregnant or of childbearing potential and has no contraception(see sections 4.3 and 4.4).
Amongst 1,823 patients treated with lenvatinib monotherapy in clinical trials, there were 5 cases(0.3%) of PRES(0.2% were Grade 3 or 4),all of which resolved after treatment and/or dose interruption, or permanent discontinuation.
Both nausea and vomiting were reported to be intermittent for the majority of patients andcan be managed by dose interruption, dose reduction and/or antiemetic therapy.
Thrombocytopenia was reported in 28.5% of patients in EBC clinical studies with trastuzumab emtansine and was the most common reported adverse reaction for all grades andgrades≥ 3, as well as the most common adverse reaction leading to treatment discontinuation(4.2%), dose interruptions, and dose reductions.